CA3043132A1 - Composes de benzodiazolium en tant qu'inhibiteurs d'enac - Google Patents

Composes de benzodiazolium en tant qu'inhibiteurs d'enac Download PDF

Info

Publication number
CA3043132A1
CA3043132A1 CA3043132A CA3043132A CA3043132A1 CA 3043132 A1 CA3043132 A1 CA 3043132A1 CA 3043132 A CA3043132 A CA 3043132A CA 3043132 A CA3043132 A CA 3043132A CA 3043132 A1 CA3043132 A1 CA 3043132A1
Authority
CA
Canada
Prior art keywords
amino
methyl
benzodiazol
ium
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3043132A
Other languages
English (en)
Inventor
Clive Mccarthy
Jonathan David HARGRAVE
Duncan Alexander HAY
Thomas Beauregard SCHOFIELD
Naomi WENT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enterprise Therapeutics Ltd
Original Assignee
Enterprise Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterprise Therapeutics Ltd filed Critical Enterprise Therapeutics Ltd
Publication of CA3043132A1 publication Critical patent/CA3043132A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule générale (I) dans laquelle R 1 , R 2 , R 3 , R 4 , R 5 et X sont tels que définis dans la description, Ces composés sont des inhibiteurs du canal sodique épithélial (ENaC) et sont utiles pour le traitement ou la prévention de maladies et d'affections respiratoires, d'affections cutanées et d'états oculaires.
CA3043132A 2016-11-22 2017-11-22 Composes de benzodiazolium en tant qu'inhibiteurs d'enac Pending CA3043132A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619694.1A GB201619694D0 (en) 2016-11-22 2016-11-22 Compounds
GB1619694.1 2016-11-22
PCT/GB2017/053499 WO2018096325A1 (fr) 2016-11-22 2017-11-22 Composés de benzodiazolium en tant qu'inhibiteurs d'enac

Publications (1)

Publication Number Publication Date
CA3043132A1 true CA3043132A1 (fr) 2018-05-31

Family

ID=57993838

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043132A Pending CA3043132A1 (fr) 2016-11-22 2017-11-22 Composes de benzodiazolium en tant qu'inhibiteurs d'enac

Country Status (21)

Country Link
US (3) US10941149B2 (fr)
EP (1) EP3544981B1 (fr)
JP (1) JP6980014B2 (fr)
KR (1) KR102517273B1 (fr)
CN (1) CN110214141B (fr)
AU (1) AU2017364308B2 (fr)
BR (1) BR112019009864A2 (fr)
CA (1) CA3043132A1 (fr)
DK (1) DK3544981T3 (fr)
EA (1) EA039607B1 (fr)
ES (1) ES2890226T3 (fr)
GB (1) GB201619694D0 (fr)
HU (1) HUE055692T2 (fr)
IL (1) IL266745B (fr)
MA (1) MA46878A (fr)
MX (1) MX2019005934A (fr)
PL (1) PL3544981T3 (fr)
PT (1) PT3544981T (fr)
TW (1) TWI756305B (fr)
WO (1) WO2018096325A1 (fr)
ZA (1) ZA201902710B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
BR112021025079A2 (pt) 2019-06-12 2022-02-15 Tmem16A Ltd Composto, uso de um composto, método para o tratamento ou profilaxia de doenças e condições afetadas pela modulação de tmem16a e composição farmacêutica
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
CN116745267A (zh) 2020-12-11 2023-09-12 跨膜蛋白16A有限公司 用于治疗呼吸系统疾病的苯并咪唑衍生物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
EP1670475A4 (fr) 2003-08-18 2009-04-15 Parion Sciences Inc Bloqueurs du canal sodique a base de pyrazinoylguanidine alaphatique
KR20060037450A (ko) 2003-08-18 2006-05-03 패리온 사이언스 인코퍼레이티드 사이클릭 피라지노일구아니딘 나트륨 채널 차단제
US7064129B2 (en) 2003-08-18 2006-06-20 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7309716B2 (en) * 2003-10-28 2007-12-18 Vertex Pharmaceuticals Incorporated Benzimidazoles useful as modulators of ion channels
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
EP2457901A1 (fr) * 2005-03-14 2012-05-30 High Point Pharmaceuticals, LLC Dérivés de benzazole, compositions et procédés d'utilisation en tant qu'inhibiteurs de secrétase B
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2008124491A1 (fr) 2007-04-03 2008-10-16 Parion Sciences, Inc. Composes de pyrazinoylguanidine destines a etre utilises en tant que modulateurs de gout
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
WO2009019506A1 (fr) 2007-08-03 2009-02-12 Astrazeneca Ab Sulfonamides hétérocycliques ayant une activité antagoniste de edg-1
WO2009074575A2 (fr) 2007-12-10 2009-06-18 Novartis Ag Composés organiques
TWI432198B (zh) 2008-02-26 2014-04-01 Parion Sciences Inc 多芳香族鈉通道阻斷劑
CA2723938A1 (fr) 2008-05-13 2009-11-19 Novartis Ag Derives d'acide 3,5-diamino-6-chloro-pyrazine-2-carboxylique et leur utilisation comme bloqueurs de canal du sodium epithelial pour le traitement de maladies des voies respiratoires
JP2011522860A (ja) 2008-06-10 2011-08-04 ノバルティス アーゲー 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
WO2011028740A1 (fr) 2009-09-03 2011-03-10 Glaxo Group Limited Bloqueurs du canal enac
WO2011079087A1 (fr) 2009-12-23 2011-06-30 Glaxo Group Limited Bloqueurs du canal enac
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
TW201204353A (en) * 2010-06-08 2012-02-01 Vertex Pharma Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GEP20186880B (en) 2011-11-02 2018-07-25 Ingelheim International Gmbh Boehringer 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
PL2855435T3 (pl) 2012-05-29 2018-10-31 Parion Sciences, Inc. Amidy o strukturze podobnej do dendrymerów, wykazujące aktywność blokerów kanałów sodowych, do leczenia zespołu suchego oka i innych chorób śluzówki
US8841309B2 (en) 2012-09-24 2014-09-23 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
US9593084B2 (en) 2012-12-17 2017-03-14 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
WO2014099673A1 (fr) 2012-12-17 2014-06-26 Parion Sciences, Inc. Composés 3,5-diamino -6-chloro-n-(n- (4-phénylbutyl)carbamimidoyl) pyrazine-2-carboxamide
CA2896686A1 (fr) 2012-12-17 2014-06-26 Parion Sciences, Inc. Composes 3,5-diamino -6-chloro-n-(n- (4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide
EP2991981B1 (fr) 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Composés de diaminopyrazine, médicaments contenant lesdits composés, leur utilisation et leurs procédés de préparation
KR20160054460A (ko) 2013-07-02 2016-05-16 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 낭성 섬유증의 치료를 위한 화합물
JP6449870B2 (ja) 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
WO2015007519A1 (fr) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Nouveaux composés benzimidazolium
WO2015007517A1 (fr) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Nouveaux composés de benzimidazolium tétra-substitués et penta-substitués
JP6461948B2 (ja) 2013-07-15 2019-01-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規５−置換ベンゾイミダゾリウム化合物
EP3030555B1 (fr) 2013-08-08 2019-01-30 Boehringer Ingelheim International GmbH Nouveaux composés d'amide de pyrazine
EP3245199B1 (fr) * 2015-01-12 2020-01-01 Boehringer Ingelheim International GmbH Composés de benzimidazolium substitués utiles pour le traitement de maladies respiratoires
WO2016113169A1 (fr) 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Composés de benzimidazolium tétra et pentasubstitués, utiles dans le traitement de maladies respiratoires
JP6847838B2 (ja) 2015-01-12 2021-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 上皮ナトリウムチャネル阻害剤としての２−（ピラジン−２−イルカルボニルアミノメチル）ベンズイミダゾリウム化合物
US9932324B2 (en) 2015-01-12 2018-04-03 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
JP6620171B2 (ja) 2015-08-20 2019-12-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規縮環フェノキシアセトアミド
MX2018002006A (es) 2015-08-20 2018-06-19 Boehringer Ingelheim Int Benzamidas apareadas novedosas.
GB201610854D0 (en) * 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
JP2019535747A (ja) 2019-12-12
IL266745A (en) 2019-07-31
BR112019009864A2 (pt) 2019-08-27
EP3544981A1 (fr) 2019-10-02
MA46878A (fr) 2019-10-02
KR20190084076A (ko) 2019-07-15
PL3544981T3 (pl) 2021-12-20
PT3544981T (pt) 2021-09-23
TWI756305B (zh) 2022-03-01
JP6980014B2 (ja) 2021-12-15
DK3544981T3 (da) 2021-09-20
US10941149B2 (en) 2021-03-09
GB201619694D0 (en) 2017-01-04
WO2018096325A1 (fr) 2018-05-31
CN110214141A (zh) 2019-09-06
US20190315757A1 (en) 2019-10-17
HUE055692T2 (hu) 2021-12-28
EA201991253A1 (ru) 2019-11-29
US20210147432A1 (en) 2021-05-20
US20240067653A1 (en) 2024-02-29
KR102517273B1 (ko) 2023-04-03
TW201833111A (zh) 2018-09-16
ES2890226T3 (es) 2022-01-18
CN110214141B (zh) 2022-05-31
EA039607B1 (ru) 2022-02-16
IL266745B (en) 2021-12-01
US11739094B2 (en) 2023-08-29
AU2017364308A1 (en) 2019-05-23
AU2017364308B2 (en) 2021-03-11
EP3544981B1 (fr) 2021-06-23
MX2019005934A (es) 2019-11-12
ZA201902710B (en) 2021-10-27

Similar Documents

Publication Publication Date Title
US11739094B2 (en) Substituted benzodiazoliums as ENaC inhibitors
EP3794002B1 (fr) Composés
ES2398428T3 (es) Derivados de triazol útiles para el tratamiento de enfermedades
US10759785B2 (en) Compounds
TWI535720B (zh) 作為ｐｉ３ｋ抑制劑之吡咯并三嗪酮衍生物
EP3697788B1 (fr) Dérivés 2-{[(3-amino-pyrazin-2-yl)formamido]méthyl}-1h-1,3-benzodiazol-3-ium substitués par bis(pentahydroxyhéxyl)amino en tant qu'inhibiteurs enac pour le traitment de maladies respirateurs
MX2015004327A (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
US20110028447A1 (en) Indazole derivatives
US20220098167A1 (en) Compounds for treating respiratory disease
EP4268824A1 (fr) Dérivés d'imidazo[2,1-f][1,2,4]triazine utiles en tant que médicament

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220728

EEER Examination request

Effective date: 20220728

EEER Examination request

Effective date: 20220728

EEER Examination request

Effective date: 20220728

EEER Examination request

Effective date: 20220728

EEER Examination request

Effective date: 20220728